HT942526JWMRPMMRDA_GG2.pdf

This broad agency announcement must be read in conjunction with the General Submission Instructions, version CD26_01.

Broad Agency Announcement for the Defense Health Agency

Joint Warfighter Medical Research Program Military Medical Research and Development Award

Funding Opportunity Number: HT942526JWMRPMMRDA

Preapplication/Preproposal Due: August 18, 2026

Application/Proposal Due: November 16, 2026

FY26 JWMRP Military Medical Research and Development Award 2

Content Before You Begin 3

Basic Information Summarizes the funding opportunity, funding details, submission deadlines and review dates

Eligibility Details eligibility factors for the applicant/offeror organization and Principal Investigator

Program Description Describes the program mission and intent of the Military Medical Research and Development Award; provides key award information and considerations; and outlines funding details

Application/Proposal Contents Presents the two-step application/proposal process and instructions for preparing a preapplication/preproposal and full application/proposal

Submission Requirements Provides locations for application/proposal packages, instructions for submitting preapplications/preproposals and full applications/proposals, and describes application/proposal verification

Review Information Outlines the processes for compliance review, preapplication/preproposal and full application/proposal selection/notification, and risk assessment. Also, details the review criteria for preapplication/preproposal screening and both tiers of the CDMRP review process – Peer Review and Programmatic Review

Federal Award Notices Outlines what a successful applicant/offeror can expect if recommended for funding

Post-Award Requirements References policy requirements for funded research; outlines reporting requirements and restrictions related to Principal Investigator changes and institutional award transfers

Other Information Outlines criteria for administrative actions including application/proposal rejection, modification, withdrawal and withhold

Appendix 1 Includes a checklist for all full application/proposal components to facilitate submission

Appendix 2 Acronym List

Appendix 3 Technology Readiness Levels and Knowledge Readiness Levels

FY26 JWMRP Military Medical Research and Development Award 3

Before You Begin

• Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application/proposal submission. User registration for each of these websites can take several weeks or longer. Each applicant/offeror must ensure their registrations are active and up to date prior to application/proposal preparation.

• Read this funding opportunity announcement in the order it is written before beginning to prepare application/proposal materials. It is the responsibility of the applicant/offeror to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.

• To support application preparation, additional resources are available including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

eBRAP Help Desk

301-682-5507 help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to preapplication/preproposal or intramural full application/proposal submission.

Grants.gov Support Center

800-518-4726 International: 1-606-545-5035 support@grants.gov

Questions regarding Grants.gov registration and Workspace.

https://sam.gov/ https://ebrap.org/eBRAP/public/index.htm https://grants.gov/register https://cdmrp.health.mil/#:%7E:text=Frequently%20Asked%20Questions%20%C2%BB https://cdmrp.health.mil/#:%7E:text=Guide%20for%20Intragovernmental%20%26%20Intramural%20Applicants https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Journey%20of%20an,Tier%20Review%20Process mailto:help@eBRAP.org mailto:support@grants.gov

Section Shortcuts Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 4

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Joint Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA) mechanism is intended to fund the logical continuation of previous Department of War (DOW)-funded research and development efforts relevant to the FY26 JWMRP that augment and accelerate high-priority medical requirements to meet the needs of Service Members and other Military Health System beneficiaries. The MMRDA supports a wide range of research projects spanning late-stage preclinical studies, late-state technology development efforts, technology demonstration, translational, and clinical research. Projects must be relevant to at least one of the FY26 JWMRP focus areas.

Distinctive Features:

To be eligible for JWMRP funding, applicants/offerors must have already received DOD/DOW core or DOD/DOW Congressional Special Interest funding.

An MMRDA Clinical Research or Clinical Trial Option (MMRDA-CRCTO) is available to specifically support clinical research/observational studies, all phases of clinical trials /interventional studies, and/or correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices and technologies. Applicants/offerors should select MMRDA-CRCTO when the application/proposal involves research that includes any human subjects, human biological samples (prospective or retrospective) or human data sets. Note: If selecting this option, applicants must submit additional relevant application/ proposal materials.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $8.8M to fund approximately two MMRDA applications/proposals with total cost caps of $1.4M per award for the MMRDA, and approximately two MMRDA-CRCTO applications/proposals with total cost caps of $3.0M per award for the MMRDA-CRCTO. The maximum period of performance is 3 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

• Preapplication/Preproposal Submission Deadline: 5:00 p.m. Eastern Time (ET), August 18, 2026

• Invitation to Submit an Application/Proposal: September 21, 2026

• Application/Proposal Submission Deadline: 11:59 p.m. ET, November 16, 2026

• End of Application/Proposal Verification Period: 5:00 p.m. ET, November 23, 2026

• Peer Review: February 2026

• Programmatic Review: April/May 2027 Announcement Type: Initial Funding Opportunity Number: HT942526JWMRPMMRDA Assistance Listing Number: 12.420

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 5

2. Eligibility Information

2.1. Eligible Applicants/Offerors

2.1.1. Organization

Extramural and intramural DOW organizations are eligible to apply, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.

Extramural Organization: A foreign or domestic non-DOW organization. Examples of extramural organizations include, but are not limited to, academic institutions, biotechnology companies, foundations, federal government organizations other than the DOW (i.e., intragovernmental organizations) and research institutes.

Intramural DOW Organization: A subset of intragovernmental organizations; refers specifically to DOW organizations, including DOW laboratories, DOW military treatment facilities, and/or DOW activities embedded within a civilian medical center.

In accordance with Department of Defense Instruction (DoDI) 5000.77 and FAR 35.017, Federally Funded Research and Development Centers (FFRDCs) are not eligible to directly receive awards under this Broad Agency Announcement (BAA). However, teaming arrangements between FFRDCs and eligible organizations are allowed as long as they are permitted under the sponsoring agreement between the federal government and the specific

FFRDC.

2.1.2. Principal Investigator

Independent investigators affiliated with an eligible organization are eligible to be named Principal Investigator (PI) on the application/proposal, regardless of ethnicity, nationality or citizenship status.

To be eligible for JWMRP funding, applicants/offerors must have already received DOD/DOW core or DOD/DOW Congressional Special Interest funding.

There are no limitations on the number of applications/proposals for which an investigator may be named as a PI.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement for contracts or assistance agreements, but may exist if Research Other Transaction (OT) or Prototype OT is the selected funding instrument.

Cost-sharing requirements for OTs are stated in 10 USC 4021 for Research OTs and 10 USC 4022 for Prototype OTs.

2.3. Other

Awards are made to eligible organizations, not to individuals. Refer to the General Submission Instructions, Appendix 1, for additional awardee qualification requirements.

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 6

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications/proposals to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the JWMRP. The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the JWMRP in 2012 to augment and accelerate high-priority DOW and service medical requirements to continue prior-year initiatives that are close to achieving their objectives and yield a benefit to military medicine. The ultimate goal of the program is to expedite the delivery of highly impactful medical solutions to Service Members and Military Health System beneficiaries; in order to ensure the highest degree of military relevance, advanced product development communities are critical partners in executing the JWMRP. Appropriations for the JWMRP from FY12 through FY25 totaled $615 million (M). The FY26 appropriation is $10M.

3.1. Award History

The JWMRP first offered awards in FY12. Since then, a total of 194 individual projects have received funding.

3.2. Intent of the Military Medical Research and Development Award

The MMRDA mechanism is intended to fund the logical continuation of previously DOW-funded research or development efforts that are relevant to the FY26 JWMRP focus areas and have the highest potential to augment and accelerate military-relevant medical product development and health care solutions for Service Members, with the potential for benefit among Veterans, military Family beneficiaries and the American public.

To be eligible for JWMRP funding, applicants/offerors must have previously received DOW core or DOW Congressional Special Interest funding (including DOW Small Business Innovation Research [SBIR]/Small Business Technology Transfer [STTR] awards) consistent with the research area being proposed for continuation under this MMRDA. Research proposed under the FY26 JWMRP MMRDA must demonstrate a logical continuation of previous DOW-funded research and development efforts with relevance to at least one of the FY26 JWMRP focus areas. If the previous DOW-funded award is no longer active, the period of performance must have been completed no more than two years prior to the preapplication/preproposal submission deadline. The funding shall be awarded at DOW discretion following a review of medical research and development gaps as well as the unfinanced medical requirements of the services. This FY26 JWMRP BAA does not support new project concepts or basic research.

The MMRDA supports research projects spanning late-stage preclinical studies, late-stage technology development efforts, technology demonstration and translational research.

The MMRDA-CRCTO supports clinical research/observational studies, all phases of clinical trials/interventional studies and/or correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices and technologies. Note: Applicants/ offerors selecting this option are required to submit additional relevant application/proposal materials, as described in Section 4.3, Full Application/Proposal Components.

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 7

3.2.1. Focus Areas for the MMRDA

The JWMRP Programmatic Panel identified the following focus areas as the highest priorities for FY26 JWMRP funding to meet critical research and development gaps and service medical requirements. To meet the intent of the funding opportunity, applications/proposals to the FY26 JWMRP must address at least one of the focus areas listed below.

• Non-vaccine approaches to prevent endemic diarrheal disease and broad-spectrum antivirals to prevent and/or treat emerging or endemic infectious diseases, excluding malaria

• Solutions to mitigate hemorrhage and/or support trauma resuscitation, including but not limited to blood, biologics and therapeutics

• Solutions to prevent and/or treat injuries due to temperature extremes (e.g., heat exhaustion, heat stroke, hypothermia and frostbite)

• Solutions to support forward treatment of musculoskeletal injuries (MSKI) and reduce impact of MSKI on operational effectiveness

• Medical countermeasures to radiation exposure, including pre-exposure prophylaxis, biodosimetry (inclusive of rapid screening and diagnostic tools), and post-exposure treatments (excluding cytokines)

3.2.2. Key Elements for the MMRDA

The following are important aspects of the FY26 JWMRP MMRDA:

Impact: The overall impact of the proposed research is a key component of this award mechanism. The application must clearly exhibit the project’s potential impact on improving the delivery of military-relevant health care solutions. High-impact research is expected to lead to the development, translation, and/or implementation of medical solutions for military application.

Relevance to Military Health: Relevance to the care of military Service Members is a key feature of this award. The proposed research should exhibit potential to augment and/or accelerate the development of materiel/knowledge products or outcomes with direct relevance to military medicine.

Technology/Knowledge Readiness: Tangible products under development must be at or above Technology Readiness Level (TRL) 5 (e.g., proof-of-concept and prototype development must be well-established in appropriate preclinical models, if applicable; non-GLP in vivo toxicity and efficacy of lead compound complete; or preliminary FDA [or equivalent] discussions complete). Studies proposing knowledge products must be at or above Knowledge Readiness Level (KRL) 5 (see Appendix 3) (e.g., ready to test a priori hypotheses using rigorous scientific design, or clinical validation of a diagnostic tool). All projects should exhibit strong potential for eventual transition to advanced development and/or implementation into military medical settings in the near future.

3.2.3. Other Important Considerations for the MMRDA

This BAA is issued under the provisions of the Competition in Contracting Act of 1984 (Public Law 98-369), as implemented in Federal Acquisition Regulation (FAR) 6.102(d)(2)(i) and 35.016 and in Department of Defense Grant and Agreement Regulations (DoDGARs) 22.315. In accordance with FAR 35.016, projects funded under this BAA must be for applied research, as well as that part of development not related to developing a specific system or hardware procurement.

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 8

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Animal research is allowed within this funding opportunity.

Clinical research (including clinical trials) is allowed within this funding opportunity.

A clinical trial is defined in the Code of Federal Regulations, Title 32, Part 219.102 (32 CFR 219.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. An intervention includes both physical procedures by which information or biospecimens are gathered, and manipulations of the subject or the subject's environment that are performed for research purposes.

Studies that do not seek to measure safety, effectiveness and/or efficacy outcome(s) of an intervention are not considered clinical trials.

For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens and/or interaction with human subjects. Clinical research is observational in nature and includes:

(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease; (b) diagnostic or detection studies (e.g., biomarker or imaging); (c) health disparity studies; and (d) development of new technologies.

(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.

(3) Outcomes research and health services research that do not fit under the definition of clinical trial.

Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under §46.104(d)(4) of the Common Rule.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE, CONSORT, SPIRIT and ARRIVE 2.0 guidelines.

Applications/proposals from investigators within the DOW and applications/proposals involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application/proposal must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

https://www.ecfr.gov/current/title-32/subtitle-A/chapter-I/subchapter-M/part-219/section-219.102 https://www.ecfr.gov/current/title-32/subtitle-A/chapter-I/subchapter-M/part-219/section-219.102 https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.104 https://www.strobe-statement.org/ https://www.nature.com/articles/s41591-025-03635-5#:%7E:text=SPIRIT%20and%20CONSORT%20are%20evidence,relevant%20empirical%20evidence%20where%20possible https://www.nature.com/articles/s41591-025-03668-w?fromPaywallRec=false https://arriveguidelines.org/arrive-guidelines

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 9

3.3. Funding Instrument

The funding instrument for awards made under this BAA will be assistance agreements, contracts, or OTs. The type of instrument used to reflect the business relationship between the organization and the government is at the discretion of the government, in accordance with the Federal Grant and Cooperative Agreement Act of 1977, as amended, 31 USC 6301-6308, which provides the legal criteria to select a procurement contract or an assistance agreement. The DHACA will also consider the use of OTs as a vehicle for award, in accordance with the conditions in 10 USC 4021 and 10 USC 4022.

An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of CDMRP during the project’s period of performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of CDMRP is anticipated, a grant will be made (31 USC 6304).

Conversely, if “substantial involvement” on the part of CDMRP is anticipated, a cooperative agreement will be made (31 USC 6305). Substantial involvement means that, after award, CDMRP staff will assist, guide, coordinate or participate in project activities.

A contract is required when the principal purpose of the instrument is to acquire property or services for the direct benefit or use of the U.S. government (31 USC 6303).

An “OT” is utilized for certain awards when the government determines execution of the project requires flexibility (10 USC 4021 and 10 USC 4022). Such flexibility may allow for incorporation of dynamic commercial industry standards and best practices or adjustment of project scope to evolving requirements of government use cases.

The award type, along with the start date, will be determined during the negotiation process.

3.4. Funding Details

Period of Performance: The maximum period of performance is 3 years.

Cost Cap: The application/proposal’s total costs budgeted for the entire period of performance should not exceed $1.4M for the MMRDA or $3.0M for the MMRDA-CRCTO. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant/offeror may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

Must be requested for:

• Travel Costs for the PI to present project information or disseminate project results at one

DOW-sponsored meeting (e.g., Military Health System Research Symposium) in Year 2 or 3 of the period of performance.

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 10

May be requested for (not all-inclusive):

• Travel in support of multi-institutional collaborations.

• Costs for one investigator to travel to one scientific/technical meeting per year in addition to the required meeting described above. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the JWMRP MMRDA or MMRDA-CRCTO.

Must not be requested for:

• Costs for travel to scientific/technical meeting(s) beyond the limits stated above.

• Tuition.

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 11

4. Application/Proposal Contents and Format

4.1. Application/Proposal Overview

Application/proposal submission is a two-step process requiring both a preapplication/ preproposal submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a full application/proposal submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application/proposal will differ.

Intramural DOW organizations submitting a full application/proposal should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application/proposal must follow instructions for submission through Grants.gov.

4.2. Preapplication/Preproposal Components

Preapplication/preproposal submissions must include the following components.

• Preapplication/preproposal Template (six-page limit): Download from eBRAP and provide responses to the questions in the FY26 JWMRP Preapplication/preproposal Template. Refer to Appendix 3, Technology/Knowledge Readiness Level Definitions. No figures, charts, graphs, or other additional material will be accepted during the preapplication/preproposal process.

4.3. Full Application/Proposal Components

Applicants/offerors must receive an invitation to submit a full application/proposal. Uninvited full application/proposal submissions will be rejected.

Each application/proposal submission must include the completed full application/proposal package for this BAA. See Appendix 1 for a checklist of the full application/proposal components.

(a) SF424 Research & Related Application for Federal Assistance Form (Grants.gov submissions only): Refer to the General Submission Instructions, Section IV.B.(a), for detailed information.

IMPORTANT: When completing the SF424 R&R, enter the eBRAP log number assigned during preapplication/preproposal submission into Block 4a – Federal Identifier.

(b) Attachments:

Each attachment of the full application/proposal components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Submission Instructions, Appendix 2.

Attachment 1: Project Narrative (20-page limit): Upload as “ProjectNarrative.pdf”.

The Project Narrative is the main body of the application/proposal. The page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs (uniform resource locators) that provide additional information that expands the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application/proposal.

https://ebrap.org/eBRAP/public/index.htm

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 12

Describe the proposed project in detail using the outline below.

− Background:

Describe the previously funded research or materiel/knowledge product development effort identified in the notification of invitation, including a description of the accomplishments and outcomes from that award. Explain how this proposed effort is a logical continuation of the previous research or materiel/knowledge product development effort.

Explain how the research has the potential to augment and/or accelerate medical product development in at least one of the FY26 JWMRP Focus Areas.

Present the scientific rationale to support the feasibility of the proposed research or materiel/knowledge product development effort, including relevant literature citations, preliminary data, and/or preclinical data that led to the development of the proposed research. The applicant/offeror may reference published or unpublished preliminary data; however, any unpublished preliminary data should originate from the laboratory of the PI or member(s) of the collaborating team.

Provide sufficient evidence to support moving into the proposed stage of research.

As applicable to the proposed research, provide a summary of relevant studies, clinical studies, or clinical trials, and distinguish how the proposed study differs from other relevant or recently completed research or clinical trials. If applicable, include a discussion of any current clinical use of the intervention under investigation and/or details of clinical trial results for other indications.

− Hypotheses/Objectives: Clearly state the hypothesis (if applicable), a purpose statement and/or the objective(s) to be reached.

− Specific Aims: Concisely explain the project’s specific aims. These aims should agree with the primary aims and associated tasks described in the Statement of Work (SOW). If this application/proposal is part of a larger study, present only tasks that this award would fund. Avoid interdependency of specific aims when possible (i.e., dependency on successful outcomes of other ongoing related research efforts).

− Research Strategy and Feasibility: Describe the proposed research strategy and feasibility of the approach, addressing the following:

Describe the study design, methods and analyses, including appropriate controls, choice of animal model (if applicable) and the endpoints/outcome measures in sufficient detail for evaluation of feasibility and effectiveness in supporting completion of the project aims.

Describe the availability of and access to the necessary study resources. If human-derived biological specimens will be used, describe the sourcing and/or acquisition of samples. If dataset(s) or human-derived specimens will be obtained from military Service Members, military Families and/or Veteran population(s), describe the feasibility of accessing the samples/dataset(s).

Explain how the study is designed to achieve reproducible and rigorous results, including (if applicable) controls, sample size estimation, power analysis, blinding, randomization and data handling

Applications/proposals that include research on animal models are also required to submit Attachment 8, Animal Research Plan.

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 13

Applications/proposals that include human subjects, human biological samples (prospective or retrospective) or human data sets are also required to submit Attachment 9, Study Population Recruitment/Sample Acquisition and Safety Plan.

Describe potential pitfalls, including interdependency of aims (i.e., dependency on successful outcomes of other ongoing related research efforts), and discuss alternative methods/approaches that may be employed to overcome them.

In addition, for applications/proposals submitted under the MMRDA-CRCTO:

Indicate whether the proposed clinical study is observational or experimental.

Include the following components, as applicable: describe the intervention, including the complete name of the investigational product, storage and handling information, source, dose, schedule, administration route and duration of the intervention. Indicate who holds the intellectual property rights to the intervention, if applicable, and how the PI has obtained access to those rights, along with access to the intervention itself, for conduct of the clinical trial.

Outline the proposed clinical study/trial methodology and study variables in sufficient detail to demonstrate a clear course of action and justification. For studies proposing clinical trials, describe the type of clinical trial to be performed (e.g., treatment, prevention, diagnostic), the phase of trial and/or class of device (as appropriate), and the study model (e.g., single group, parallel, crossover).

Identify and describe the observation/intervention and the projected outcomes.

Describe how the outcomes address current clinical needs and how they compare with currently available standards of care.

Provide a schedule (e.g., flowchart or diagram) of study observations/ interventions, evaluations, and follow-up procedures, including any data or sample collection.

Explain how the study is designed to achieve reproducible and rigorous results, including (if applicable) controls, sample size estimation, power analysis, blinding, randomization and data handling. Provide an estimate of the recruitable population and the enrollment target. Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported. Describe any measures to reduce bias.

Describe the statistical plan and the rationale for the statistical methodology, including the sample size projections and as applicable, any subgroup analyses.

If applicable, explain how the statistical plan compensates for the use of a subpopulation within the recruited sample population to ensure appropriate power can be achieved within the subpopulation.

Describe data collection and handling, including rules for stopping data collection, how outliers will be defined and handled, and identification of primary endpoints/outcomes.

Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”. Begin each document on a new page. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures or drawings. These items should be included in the Project Narrative. Submitting material that is not requested may be viewed as an attempt to gain an unfair competitive advantage; such material will

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 14 be removed, or the application/proposal may be administratively withdrawn. Letters of support not requested in the broad agency announcement, such as those from members of Congress, will be removed from the application/proposal package.

References Cited: List the references cited in the Project Narrative using a standard reference format (include URLs, if available).

List of Abbreviations, Acronyms and Symbols: Provide a list of abbreviations, acronyms and symbols.

Facilities, Existing Equipment and Other Resources: Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.

Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

Letters of Support (two-page limit per letter is recommended): Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI’s Department Chair, or appropriate organization official, should also confirm that the PI(s) meet eligibility criteria. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

Sex as a Biological Variable Strategy (two-page limit is recommended):

Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.

Background and Proprietary Information: Provide a list of all background intellectual property to be used in the project or provide a statement that none will be used. All software and data first produced under this BAA are subject to a federal purpose license. Therefore, it is important to disclose/list any intellectual property (software, data, patents, etc.) that will be used in performance of the project. If applicable, all proprietary information to be provided to the government should be stated and identified; the applicant/offeror should indicate whether a waiver of the federal purpose license will be required. Additional information can be found in the 2 CFR 200.315, “Intangible Property.”

https://cdmrp.health.mil/pubs/pdf/CDMRP%20SABV%20Directive_Revised_MAR2025_signed.pdf https://cdmrp.health.mil/pubs/pdf/CDMRP%20SABV%20Directive_Revised_MAR2025_signed.pdf

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 15

Research Sharing Plan: Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Do not submit a copy of the National Institutes of Health Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.

Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP’s expectations for making data and research resources publicly available.

Quad Chart: Provide a Quad Chart for the proposed project. The format for the quad chart is available on the eBRAP “Funding Opportunities & Forms” webpage.

Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”. The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Use only characters available on a standard QWERTY keyboard; spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

Background: State how the proposed research addresses at least one of the FY26

JWMRP Focus Areas. Present the scientific rationale behind the proposed work.

Include the current TRL/KRL of the product or knowledge outcome (must be 5 or greater), and the estimated target TRL/KRL upon completion of the proposed research. See Appendix 3 for TRL/KRL guidance.

Hypothesis/Objective(s): State the hypothesis and/or objective(s).

Specific Aims: State the specific aims of the study.

Study Design: Describe the study design, including appropriate controls. For applications/proposals that include clinical trials, state the type of clinical trial proposed (e.g., treatment, prevention, diagnostic), the phase of the trial, the class of device (as appropriate), and the study model (e.g., single group, parallel, crossover).

State the proposed intervention and the primary projected outcome(s) of the clinical trial.

https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Directive%20on%20Sharing%20Data%20and%20Research%20Resources https://ebrap.org/eBRAP/public/Program.htm

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 16

Impact and Military Relevance: Highlight the likely contributions of the initiative to augment and/or accelerate a materiel/knowledge product development effort.

Describe the military health relevance. Briefly explain how the proposed project will have an immediate or potential long-term benefit expected to have a major impact on the health and well-being of Service Members, with the potential to benefit military Families, Veterans and/or the American public.

Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”. The lay abstract is used by all reviewers and addresses issues of particular interest to the affected community. Abstracts of all funded research projects will be posted publicly. Use only characters available on a standard QWERTY keyboard; spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed. Do not duplicate the technical abstract.

The lay abstract should address the points outlined below in a manner that is readily understood by readers without a background in science or medicine. Avoid overuse of scientific jargon, acronyms and abbreviations.

– Summarize the objectives and rationale for the proposed research.

– What population will the research help, and how will it help them?

– What are the potential applications, benefits and risks of the anticipated outcomes?

– What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?

– Describe how the results of the proposed study will ultimately benefit military Service

Members.

Attachment 5: Statement of Work (six-page limit): Upload as “SOW.pdf”. Refer to eBRAP for the Suggested SOW Format.

For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

Attachment 6: Impact Statement and Military Relevance Statement (two-page limit): Upload as “Impact.pdf”. The impact statement should address the points outlined below written in a manner that is readily understood by readers without a background in science or medicine.

Explain why the proposed research or materiel/knowledge product development effort is important and relevant to the role of the JWMRP in addressing high-priority DOW medical requirements and capability gaps. Additionally, describe how the effort will accelerate the development of products that will impact the Warfighter within the context of the FY26 JWMRP Focus Area(s) addressed by the application/proposal.

Describe the potential impact on military populations. Provide information about the incidence and/or prevalence of the disease or condition in military populations (if known).

Describe how the proposed product/knowledge will lead to the development and eventual translation of therapeutic or technological advances in the care of military https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Suggested%20SOW%20Format https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Example%3A%20Assembling%20a%20Clinical%20Research%20and/or%20Clinical%20Trial%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Example%3A%20Assembling%20a%20Clinical%20Research%20and/or%20Clinical%20Trial%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Example%3A%20Assembling%20a%20Generic%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Example%3A%20Assembling%20a%20Generic%20Statement%20of%20Work

Basic Information | Eligibility | Program Description | Application/Proposal Contents | Submission Requirements Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 JWMRP Military Medical Research and Development Award 17

Service Members with the potential to benefit military Family beneficiaries, Veterans and the American public.

Describe how the research will result in improvement over currently available military health care standards and practices.

Describe the short-term impact. Detail the anticipated short-term outcome(s)/ product(s) (knowledge and/or materiel) of the proposed research or knowledge/ materiel product development effort, and describe how they will impact the relevant populations.

Describe how the study will augment and/or accelerate product development, as applicable.

If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

Attachment 7: Post-Award Transition Plan (three-page limit): Upload as “Transition.pdf”. Discuss the anticipated methods and strategies necessary to move the anticipated research outcome (e.g., knowledge, methodology, product, intervention) to the next phase of development (e.g., next-phase clinical trials, approval by a Regulatory Agency, commercialization/transition to industry, incorporation into clinical practice, and/or delivery to the civilian or military market) assuming successful completion of the award. Applicants/offerors are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan.

Applicants/offerors are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the research outcome into the next phase of development. The post-award transition plan should:

− Name the project’s anticipated research outcomes including knowledge products and/or clinical products for development. A “knowledge product” is a non-materiel product that aims to transition into medical practice, training, tools or to support materiel solutions; and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.

− Demonstrate how the proposed product or knowledge outcome is currently at a minimum TRL/KRL of 5 and estimate the target TRL/KRL upon completion of the proposed research.

− Include a timeline with defined milestones for transitioning the anticipated research outcomes to the next phase of development. Include steps toward Regulatory Agency approval, if applicable. Describe the steps necessary to adapt and transition the knowledge/product/intervention from civilian application to military fielding/ adoption/use.

− Describe current or planned collaborations and other resources (e.g., DOW partners, clinical partners, commercial partners, manufacturing partners, clinical practice guideline development committees, training providers/resources) to execute the steps toward regulatory approval. Include a discussion of the funding strategy necessary to transition the research outcome to the next level of investigation, development and/or commercialization. This may include commercial sponsorship, venture capital, federal or non-federal funding opportunities, etc.